Further, inhibition of PRMT5 in B cell lymphoma resulted in markedly upregulation of BCL6 target genes, and concomitant inhibition of both BCL6 and PRMT5 exhibited synergistic killing of BCL6‐expressing lymphoma cells. The gene discussed is PRMT5; the disease is B-cell non-Hodgkin lymphoma.